Impact of Disease Progression on Healthcare Resource Utilization and Quality of Life in Patients With Hypertrophic Cardiomyopathy: A Real-World Cross-Sectional Survey
Author(s)
Paulos Gebrehiwet, PhD1, James Jackson, BA2, Lucy Hancock, BSc Biomedical Science2, Sophie Barlow, MSc2, Laura LeBrocq, BSc Psychology2, Emily Green, BSc2, Mike Butzner, Jr., DrPH1, Sanatan Shreay, PhD, MS1, Keitaro Akita, PhD3, Yuichi Shimada, MD3.
1Cytokinetics Incorporated, South San Francisco, CA, USA, 2Adelphi Real World, Bollington, United Kingdom, 3Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
1Cytokinetics Incorporated, South San Francisco, CA, USA, 2Adelphi Real World, Bollington, United Kingdom, 3Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
OBJECTIVES: To evaluate the effect of disease progression on healthcare resource utilization (HCRU) and quality of life (QoL) in patients with hypertrophic cardiomyopathy (HCM).
METHODS: Data were drawn from the Adelphi HCM Disease Specific Programme™, a real-world, cross-sectional survey with retrospective data collection in Italy, Spain and United States between 2022-2024. Disease progression was assessed using Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) quartiles and current New York Heart Association (NYHA) class. KCCQ-CSS quartiles were defined as:Q1>0-≤70; Q2>70-≤83; Q3>83-≤92; and Q4>92-≤100. HCRU in the past 12 months were HCM-related hospitalizations, emergency room (ER) visits, day visits, caregiver support. QoL was measured using EQ-5D-5L. Mean values of HCRU and QoL were reported. Spearman’s rank assessed associations between disease progression, HCRU and EQ-5D-5L.
RESULTS: Of 1909 patients, mean age was 56.48 and 60.71% were male. KCCQ-CSS and NYHA class were available for 286 and 1909 patients with HCM, respectively. Lower KCCQ-CSS was associated with increased number of HCM-related hospitalizations (Q1=0.22, Q2=0.09, Q3=0.03, Q4=0.00, p<0.0001), ER visits (Q1=0.11, Q2=0.05, Q3=0.02, Q4=0.02, p=0.0140), day visits (Q1=0.93, Q2=0.61, Q3=0.33, Q4=0.09, p<0.0001) and caregiver support in hours per week (Q1=20.97, Q2=11.29, Q 3=9.46, Q4=4.23, p<0.0001). Mean EQ-5D-5L score decreased with lower KCCQ-CSS scores (Q1=0.70, Q2=0.83, Q3=0.90, Q4=0.97, p<0.0001). Higher NYHA class was associated with increased number of hospitalizations (NYHA I=0.09, NYHA II=0.11, NYHA III/IV=0.53, p<0.0001), ER visits (I=0.04, II=0.08, III/IV=0.28, p<0.0001), day visits (I=0.59, II=0.72, III/IV=1.42, p<0.0001) and caregiver support in hours per week (I=0.78, II=10.39, III/IV=29.36, p<0.0001). Mean EQ-5D-5L score decreased with higher NYHA class (I=0.92, II=0.86, III/IV=0.73, p<0.0001).
CONCLUSIONS: In patients with HCM, HCRU increased and QoL deteriorated with disease progression, as measured by KCCQ-CSS and NYHA class. Effective treatments that help lower HCRU and improve QoL are needed to reduce the economic and humanistic burden of HCM for patients and healthcare systems.
METHODS: Data were drawn from the Adelphi HCM Disease Specific Programme™, a real-world, cross-sectional survey with retrospective data collection in Italy, Spain and United States between 2022-2024. Disease progression was assessed using Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) quartiles and current New York Heart Association (NYHA) class. KCCQ-CSS quartiles were defined as:Q1>0-≤70; Q2>70-≤83; Q3>83-≤92; and Q4>92-≤100. HCRU in the past 12 months were HCM-related hospitalizations, emergency room (ER) visits, day visits, caregiver support. QoL was measured using EQ-5D-5L. Mean values of HCRU and QoL were reported. Spearman’s rank assessed associations between disease progression, HCRU and EQ-5D-5L.
RESULTS: Of 1909 patients, mean age was 56.48 and 60.71% were male. KCCQ-CSS and NYHA class were available for 286 and 1909 patients with HCM, respectively. Lower KCCQ-CSS was associated with increased number of HCM-related hospitalizations (Q1=0.22, Q2=0.09, Q3=0.03, Q4=0.00, p<0.0001), ER visits (Q1=0.11, Q2=0.05, Q3=0.02, Q4=0.02, p=0.0140), day visits (Q1=0.93, Q2=0.61, Q3=0.33, Q4=0.09, p<0.0001) and caregiver support in hours per week (Q1=20.97, Q2=11.29, Q 3=9.46, Q4=4.23, p<0.0001). Mean EQ-5D-5L score decreased with lower KCCQ-CSS scores (Q1=0.70, Q2=0.83, Q3=0.90, Q4=0.97, p<0.0001). Higher NYHA class was associated with increased number of hospitalizations (NYHA I=0.09, NYHA II=0.11, NYHA III/IV=0.53, p<0.0001), ER visits (I=0.04, II=0.08, III/IV=0.28, p<0.0001), day visits (I=0.59, II=0.72, III/IV=1.42, p<0.0001) and caregiver support in hours per week (I=0.78, II=10.39, III/IV=29.36, p<0.0001). Mean EQ-5D-5L score decreased with higher NYHA class (I=0.92, II=0.86, III/IV=0.73, p<0.0001).
CONCLUSIONS: In patients with HCM, HCRU increased and QoL deteriorated with disease progression, as measured by KCCQ-CSS and NYHA class. Effective treatments that help lower HCRU and improve QoL are needed to reduce the economic and humanistic burden of HCM for patients and healthcare systems.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
CO137
Topic
Clinical Outcomes
Topic Subcategory
Clinician Reported Outcomes
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory)